Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152) - Wikidata - awgldk - TriplyDB

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

http://www.wikidata.org/entity/Q27678027

about

OTUB1 modulates c-IAP1 stability to regulate signalling pathways Targeting Cell Survival Proteins for Cancer Cell Death Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics Small-molecule SMAC mimetics as new cancer therapeutics Apoptotic agents Motif mediated protein-protein interactions as drug targets Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.Targeting protein-protein interactions as an anticancer strategy Inhibitor of apoptosis proteins (IAPs) may be effective therapeutic targets for treating endometriosis.Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein.Alternative modulation of protein-protein interactions by small molecules High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists High Concentrations of TNF-α Induce Cell Death during Interactions between Human Umbilical Cord Mesenchymal Stem Cells and Peripheral Blood Mononuclear Cells New Frontiers in Druggability Lipid-conjugated Smac analogues.An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene.Pathophysiological Significance of Hepatic Apoptosis IAP proteins as targets for drug development in oncology IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152 Binding of small molecules at interface of protein-protein complex - A newer approach to rational drug design.The LEF1/CYLD axis and cIAPs regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer cells.Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale.Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.Manipulating the apoptotic pathway: potential therapeutics for cancer patients.Small molecules as pro-apoptotic anticancer agents.NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions.Targeting the inhibitor of Apoptosis Protein BIR3 binding domains.X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy.Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease.Discovery of Novel, Potent, and Specific Cell-Death Inducers in the Jurkat Acute Lymphoblastic Leukemia Cell Line.

P2860

Q24337266-4A680585-DE1E-49C3-B23D-816EA010A748 Q26765447-4A32C506-465E-4ECE-92CA-81F6D8A3F631 Q26775356-F2F22166-FF9F-440B-93E1-9EE4BABCFE84 Q26864204-F17760E2-F759-4CAB-9148-5A2DBA2E5514 Q27016160-B7DD6E39-A878-40D8-B76B-5EAE8C2A0CF1 Q28079554-C2B6B22E-BAFF-4BEF-99BE-F7EB22B79F4D Q28283505-7F71D35B-C5D7-4F15-A244-96D96D7E211B Q33841579-60269568-72F9-4FE8-9B40-AB2A3E6808A1 Q34263719-75A4E986-06A4-4AE0-93CE-CCF8E23C6930 Q34347892-FD7C1C9B-899B-4551-A8FF-1747419EB436 Q34673169-33AEEEB7-A4E8-41FC-A070-5F329ACE8E61 Q35072876-D7C2880E-D6F9-4796-ADBF-D352FCC4BDD2 Q35119355-4BE6540C-5EC9-4BFE-98E2-7D925A143C18 Q35338435-3CFD4FD7-9F4C-4C81-8866-039D23237D74 Q35484644-97ECA096-C0C6-47B4-8E80-6CF85E3FF046 Q35551870-D4039C1E-9A07-4903-A943-DBCAA1966B55 Q35620999-504FB2FF-8EA0-463E-9B29-6595712C41D8 Q35634594-BC8D0616-9E96-47F4-8E9A-F55DEE772898 Q35645956-1CFAA3E1-7340-4DE8-A270-7A4E995509F3 Q35730955-368216C6-3C76-4F5B-8316-C2B07D8AB34D Q35780628-064E9AAA-2148-4F2C-A44D-7F7317027057 Q35941858-2C610631-ED9F-4C94-AD7A-377A7046F17C Q36501732-42F1285A-ACC9-47AA-AE4D-DE8610787E31 Q36788045-AFB38E2E-AE6A-45C8-BBEB-7BB726430734 Q36961965-331E1710-9325-44A4-99E1-E32909DA4800 Q37209606-F4532CB4-7B88-4677-AB85-ADCEA5E4B3CC Q37376164-5265C48F-73F1-4607-9F62-DCB734FF0753 Q37412477-8D3D5F54-058C-4B05-9EEC-22919666B800 Q37610874-008804F5-52D0-4589-B433-FB142208879C Q37620626-CEFB3B3B-C286-4DDC-A93A-78B0838AE5F4 Q37654710-72EDDCEC-EABA-444F-A7C5-8BDAC5B84D27 Q37702716-34E7BBA9-3EFD-40A5-B8D7-72614007457E Q38115574-279F8688-495A-4291-BCB9-C18CD62C5D8F Q38162939-55DE2CF7-65FE-48D1-A689-5E6F954711B9 Q38203020-5EF88050-819C-49DE-A6B2-82760121DE57 Q38226672-9F8BDFFC-34C8-410E-9D83-9940843BDE85 Q38239689-661BE2F1-DB20-437E-A03A-CBF2AAA54A5A Q38252591-602A31AA-FDCD-4849-BB0B-334F160B7E84 Q38707914-75A4F9C0-AA26-4A3E-A480-BCA136A3984E Q38844170-9B0BAACB-DC12-4D86-B129-2834844F6D61

P2860

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

http://www.wikidata.org/entity/Q27678027

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@ast

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@en

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@nl

type

label

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@ast

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@en

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@nl

prefLabel

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@ast

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@en

Discovery of a Potent Small-Mo ...... Treatment of Cancer (GDC-0152)

@nl

P1433

Q27678027-2DFCEFD2-CDFF-420F-8D0B-358D46425C8E

P1476

Q27678027-84BCB15A-9FF9-49DB-8C98-04CD19491980

P2093

Q27678027-088BE965-837C-472D-8A93-847112064233

Q27678027-102B7BF6-0A7B-4EB5-8EC6-AD31FE6C0FA3

Q27678027-10CE4ACE-8DF6-4FD9-8A58-D6EC95F49FDB

Q27678027-130D5F0F-E713-4FFD-8C8D-54F2BCFD59C6

Q27678027-1B8E0730-C09E-44C2-B71E-239971F66B2B

Q27678027-1C7621EF-5D82-4100-B41B-8D742F382CBF

Q27678027-2319F6BD-BFAC-4254-8072-81A4E2F7FEE1

Q27678027-248C47CA-FFE2-42E5-8E23-DE22084D1D72

Q27678027-389C14F2-B588-430D-A52D-0547023CD734

Q27678027-459DD763-FCA5-42FC-B03A-F6CD76DC51D3

P2860

Q27678027-10D66F0F-C638-4A1B-8D8D-D3E574E99DB6

Q27678027-11D0D711-93A0-4DFF-A772-A54AC4FA108E

Q27678027-1C80FC52-5303-4E0A-86AF-1207C3E6D49F

Q27678027-1CD36FF2-9861-4AE1-9168-1319897D5B36

Q27678027-2E8F741B-A29F-4CB5-A01B-DD08BA451838

Q27678027-3373EA0E-86E3-4BE4-88D7-F065663DF6C0

Q27678027-36A4BEC5-35BE-4C14-A04C-9C56F20E88ED

Q27678027-40ED0CF8-4EEF-4623-A08D-5BFCD6259E92

Q27678027-46D8BD9B-0F8E-43BC-BEA5-79FD096E4EE5

Q27678027-48536990-FBE5-40F9-9B80-0F610D302469

P304

Q27678027-C9B9A7A5-1746-484B-B281-C912236CEE3B

P31

Q27678027-E77DA4AC-9D38-4DFD-BC2C-02B927AB3559

P3181

Q27678027-771775E2-02FE-4A77-9DFA-025710D3D32C

P356

Q27678027-4E1D17B9-B0C5-42E1-BFD7-5B11C4CDCA62

P407

Q27678027-5EEEEDED-64F9-4596-AD30-09DDB9240ADF

P433

Q27678027-D0291DBD-5B51-458F-9940-9A1C671F9F42

P478

Q27678027-38E3C5BD-EABA-400B-AAA0-D8EB731C6724

P50

Q27678027-ACBB7868-44EB-4312-AED0-0FC52ACF876E

P577

Q27678027-46ACA46F-E21E-4DB9-863F-FD83EA4A0D23

P5875

Q27678027-7CCE64D2-7D36-4C8C-AFB1-60E99A62A13A

P698

Q27678027-A0BC81C2-1867-4F22-B98C-C602FEAACFD8

P921

Q27678027-38859F7C-F043-477A-AA02-138EE2E670BC

Q27678027-CD00CC0A-1E4D-4F3A-9F51-A1092B502522

P932

Q27678027-C9360442-FBD8-4190-B86D-671D438E86E3

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of a potent small-mo ...... treatment of cancer (GDC-0152)

@en

P2093

Andrew J Wagner

http://www.w3.org/2001/XMLSchema#string

Bainian Feng

http://www.w3.org/2001/XMLSchema#string

Brigitte Maurer

http://www.w3.org/2001/XMLSchema#string

Clifford Quan

http://www.w3.org/2001/XMLSchema#string

Domagoj Vucic

http://www.w3.org/2001/XMLSchema#string

Emile Plise

http://www.w3.org/2001/XMLSchema#string

Eugene Varfolomeev

http://www.w3.org/2001/XMLSchema#string

Frederick Cohen

http://www.w3.org/2001/XMLSchema#string

Hank La

http://www.w3.org/2001/XMLSchema#string

Harvey Wong

http://www.w3.org/2001/XMLSchema#string

P2860

ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas

Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain

Structural basis for the inhibition of caspase-3 by XIAP

IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition.

Mechanism of XIAP-mediated inhibition of caspase-9

IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis

c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation

The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites

NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP

NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP

P304

4101-4113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4131059

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM300060K

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Stephen G. Young

P577

2012-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221891837

http://www.w3.org/2001/XMLSchema#string

P698

22413863

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

3366583

http://www.w3.org/2001/XMLSchema#string